Centessa Pharma rises on early-stage data for sleep disorder drug

Centessa Pharmaceuticals

10/09/2024 15:01

** U.S.-listed shares of drug developer Centessa
Pharmaceuticals  CNTA.O  rise 11.55% to $16.66
    ** Co says ORX750, which treats acute sleep deprivation,
showed statistically significant improvement in mean sleep
latency - time it takes for a person to fall asleep - at 1 mg
and 2.5 mg doses in comparison to placebo in early-stage study
    ** CNTA says a 2.5 mg dose of the treatment restored
normative wakefulness with mean sleep latency of 32 minutes, as
measured by the Maintenance of Wakefulness Test
    ** Including session's gains, stock has more than doubled
YTD

 (Reporting by Kashish Tandon in Bengaluru)
 ((Kashish.tandon@thomsonreuters.com))